Adverse events198

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 198

Type	Event	Organ system	Group	Affected	At risk
other	Hereditary Angioedema	Congenital, familial and genetic disorders	Controlled Phase- Icatibant (Randomized Subjects )	10	36
other	Hereditary Angioedema	Congenital, familial and genetic disorders	Controlled Phase- Tranexamic Acid (Randomized Subjects)	6	38
other	Hereditary Angioedema	Congenital, familial and genetic disorders	Controlled Phase- Icatibant (Subjects w/ Laryngeal Attack)	1	3
other	Hereditary Angioedema	Congenital, familial and genetic disorders	Open Label Extension Phase- Icatibant (Previously Randomized)	10	44
other	Hereditary Angioedema	Congenital, familial and genetic disorders	Open Label Extension Phase (Subjects w/ Laryngeal Attack)	1	2
other	Hereditary Angioedema	Congenital, familial and genetic disorders	Open Label Extension Phase(Untreated Patients at the Baseline	1	8
other	Injection Site Reaction	General disorders	Controlled Phase- Icatibant (Randomized Subjects )	2	36
other	Injection Site Reaction	General disorders	Controlled Phase- Tranexamic Acid (Randomized Subjects)	0	38
other	Injection Site Reaction	General disorders	Controlled Phase- Icatibant (Subjects w/ Laryngeal Attack)	0	3
other	Injection Site Reaction	General disorders	Open Label Extension Phase- Icatibant (Previously Randomized)	1	44
other	Injection Site Reaction	General disorders	Open Label Extension Phase (Subjects w/ Laryngeal Attack)	0	2
other	Injection Site Reaction	General disorders	Open Label Extension Phase(Untreated Patients at the Baseline	0	8
other	Nasopharyngitis	Infections and infestations	Controlled Phase- Icatibant (Randomized Subjects )	2	36
other	Nasopharyngitis	Infections and infestations	Controlled Phase- Tranexamic Acid (Randomized Subjects)	3	38
other	Nasopharyngitis	Infections and infestations	Controlled Phase- Icatibant (Subjects w/ Laryngeal Attack)	0	3
other	Nasopharyngitis	Infections and infestations	Open Label Extension Phase- Icatibant (Previously Randomized)	4	44
other	Nasopharyngitis	Infections and infestations	Open Label Extension Phase (Subjects w/ Laryngeal Attack)	0	2
other	Nasopharyngitis	Infections and infestations	Open Label Extension Phase(Untreated Patients at the Baseline	0	8
other	Pharyngitis	Infections and infestations	Controlled Phase- Icatibant (Randomized Subjects )	0	36
other	Pharyngitis	Infections and infestations	Controlled Phase- Tranexamic Acid (Randomized Subjects)	1	38

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00500656/events

API reference For AI assistants

Adverse events198

Sources 3

Read this list from software.